<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1137">
  <stage>Registered</stage>
  <submitdate>25/02/2006</submitdate>
  <approvaldate>1/03/2006</approvaldate>
  <actrnumber>ACTRN12606000088549</actrnumber>
  <trial_identification>
    <studytitle>Preoperative intranenous N-Acetylcysteine for the prevention of renal failure in patients with renal impairment undergoing cardiac surgery</studytitle>
    <scientifictitle>Preoperative intranenous N-Acetylcysteine for the prevention of renal failure in patients with renal impairment undergoing cardiac surgery</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Renal Impairment in cardiac surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients who fit into Inclusion criteria will be randomised to receive intravenous N-Acetylcestine 150mg/kg for 16 hours.</interventions>
    <comparator>Patients who fit into Inclusion criteria will be randomised to receive intravenous Placebo the day before surgery.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Occurrence of acute renal failure as defined by an increase in serum creatinine of greater than or equal to 44umol/L over the baseline value or an increase in creatinine of greater than 50% above baseline or a reduction in calculated creatinine clearance of 50%.</outcome>
      <timepoint>Measured on days 1, 3 and 5.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Peak serum creatinine level </outcome>
      <timepoint>Within 5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Creatinine clearance </outcome>
      <timepoint>Day 1, 3 and 5</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cystatin C levels</outcome>
      <timepoint>Pre-op, day 1, 3 &amp; 5</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Requirement for dialysis in hospital</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of ICU stay</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of hospital stay</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In hospital mortality rate.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patients with chronic stable renal impairment as evidenced by a creatinine &gt;133Âµmol//L or creatinine clearance &lt; 50ml/min as estimated by the Cockcroft- Gault formula20. ( Creatinine clearance or CrCl will be calculated by applying the Cockcroft- Gault formula to the baseline serum creatinine level: (140  age) x weight/ serum creatinine x 0.815; with a female adjustment: CrCl female = CrCl x 0.85)2. Patients undergoing cardiac surgery requiring cardiopulmonary bypass including but not exclusive to coronary artery bypass grafting (CABG), valve surgery, combination CABG and valve replacement procedures, adult patients undergoing surgery for congenital heart disease, repairs of ventricular aneurysm, septal defect repairs and removal of myxomas, stable patients with intraaortic balloon pump (IABP) inserted electively preoperatively, redo cases requiring cardiopulmonary bypass (CPB). 3. Patients who have given consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Females of child bearing age in whom pregnancy has not been disproved, are pregnant or lactating. 2. Haemodynamically unstable patients with SBP&lt; 90mmHg preoperatively. 3. Patients with acute renal failure. 4. Patients receiving haemodialysis or peritoneal dialysis. 5. Treatment with nonsteroidal anti-inflammatory agents (NSAIDs) within previous 4 days. 6. Patients allergic to acetylcysteine. 7. Patients with current acute exacerbations of asthma or chronic obstructive pulmonary disease. 8. Impaired liver function. 9. Renal transplant patients.10. Failure to consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered sealed envelopes</concealment>
    <sequence>Random computer generation in blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/08/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Prince of Wales Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Intensive care research fund</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Prince of Wales ethics</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/07/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Yahya Shehabi</name>
      <address>Intensive Care Unit
Prince of Wales Hospital
Level 1
Dickinson Building
Barker St
Randwick NSW 2031</address>
      <phone>+61 2 93824721</phone>
      <fax>+61 2 93824870</fax>
      <email>yshehabi@ozemail.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Naomi Hammond</name>
      <address>Intensive Care Unit
Prince of Wales Hospital
Level 1
Dickinson Building
Barker St
Randwick NSW 2031</address>
      <phone>+61 2 93824720</phone>
      <fax>+61 2 93824748</fax>
      <email>naomi.hammond@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>